Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease - Who should receive it?

Acta Paediatrica, International Journal of Paediatrics

Volumn 95, Issue 4, 2006, Pages 388-390

  Sunnegårdh, Jan ^a  

^a QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

Author keywords

Congenital heart defects; Palivizumab prophylaxis; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB;

CHILD HOSPITALIZATION; CONGENITAL HEART DISEASE; HUMAN; IMMUNOPROPHYLAXIS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT OUTCOME; VIRAL RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; HEART DEFECTS, CONGENITAL; HOSPITALIZATION; HUMANS; INFANT; PATIENT SELECTION; PRACTICE GUIDELINES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 33646713930     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1080/08035250500544955     Document Type: Review

References (26)

1. Morris JA, Blount RE Jr, Savage RE. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med 1956;92:544-9.
2. Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to Chimpanzee corya agent (CCA). Am J Hyg 1957;66:281-90.
3. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchioloitis-associated hospitalizations among US children,1980-1996. JAMA 1999;282:1440-6.
4. Meissner HC, Welliver RC, Chartrand SA, Chartrand S, Law B, Weisman L, et al. Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999;18:223-31.
5. Sigurs N, Bjarnarson R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000;161:1501-7.
6. Piedimonte G, King KA, Holmgren NL, Bertrand PJ, Rodriguez MM, Hirsch RL. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Pediatr Res 2000;47:351-6.
7. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969;89:405-21.
8. Kahn JS. Respiratory syncytial virus vaccine development. Curr Opin Pediatr 2000;12:257-62.
9. Black CP. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care 2003;48:209-31.
10. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory virus infection in high-risk infants. Pediatrics 1998;102:531-7.
11. Feltes TF, Cabalka AK, Meissner HC, Piazza F, Carlin D, Top F, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40.
12. Meberg A, Bru A-L. Respiratory syncytial virus infections in congenital heart defects - hospitalizations and costs. Acta Paediatr 2006;95:404-6.
13. Hoffman JI. Incidence of congenital heart disease: I. Postnatal incidence. Pediatr Cardiol 1995;16:103-13.
14. Wren C, O'Sullivan J. Survival with congenital heart disease and need for follow up in adult life. Heart 2001;85:1059-68.
15. Sunnegårdh J, Jansson J, Nygren A. Respiratory syncytial virus (RSV) infection in infants with significant congenital heart disease. Cardiol Young 2004;14 Suppl 2:87-8 (abstract).
16. Khongphatthanayothin A, Wong PC, Samara Y, Newth C, Wells W, Starnes VA, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med 1999;27:1974-81.
17. Thorburn K, Kerr S, Taylor N, van Saene H. RSV outbreak in a paediatric intensive care unit. J Hosp Infect 2004;57:194-201.
18. Bonnet D, Schmaltz A, Feltes T. Infection by the respiratory syncytial virus in infants and young children at high risk. Cardiol Young 2005;15:256-65.
19. Yount L, Mahle W. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics 2004;114:1606-11.
20. Rackham O, Thorburn K, Kerr S. The potential impact of prophylaxis against bronchiolitis due to the respiratory syncytial virus infection in children with congenital heart malformations. Cardiol Young 2005;15:251-5.
21. Onuzo O. Re: Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease. Cardiol Young 2004;14:469.
22. Sandvik A. Bergning av kostnadsvekter til den norske versionen av DRG-systemet. Rapport nr. STF 7803583. SINTEF Unimed 2003.
23. American Academy of Pediatrics Committee on Infections Disease and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus intravenous immune globulin for the prevention of respiratory syncytial infections. Pediatrics 2003;112:1442-6.
24. Tulloh R, Marsh M, Blackburn M, Casey F, Lenney W, Weller P, et al. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital heart disease. Cardiol Young 2003;13:420-3.
25. Tulloh R, Feltes T. The European Forum for Clinical Management: prophylaxis against respiratory syncytial virus in infants and young children with congenital heart disease. Cardiol Young 2005;15:274-8.
26. Handläggning av RSV-infektion hos hjärtsjuka barnkompletterande information. Information från Läkemedelsverket 2004;4:29-31.